CRISPR Therapeutics AG News
Cathie Wood Defends Strategy: Innovation 'Solves Problems'
'Innovation tends to gain traction during difficult times because it solves problems,' the prominent asset manager Cathie Wood says in a webinar.
Cathie Wood's Flagship Fund Keeps Falling
Ark Innovation ETF recently traded at $36.95, not far from its pandemic-low close of $34.69 on March 18, 2020.
This CRISPR Stock Plunged On Cell Therapy's Looming Question
A certain type of cell therapy is easier to manufacture, but may lead to worse long-term outcomes for patients.
bluebird bio (Finally) Nears Approval. What's Next?
The gene therapy pioneer may earn approval years after initially teasing investors. It may not be time to celebrate.
Cathie Wood Hints at New Fund With Private Investments
Asset manager Cathie Wood hinted that she'd start up a fund that would include private investments.
Morgan Stanley Stock Leads Gains As Banks Boost Dividends After Fed Stress Tests
Morgan Stanley, Wells Fargo, Bank of America and Goldman Sachs will lift their quarterly dividend, while JPMorgan will hold its steady following last week's Fed stress tests.
Nike Stock Slides As As Margin Pressures, China Worries Offset Q4 Earnings Beat
"We think we're well positioned for growth in fiscal year 2023 ... having said that, we did take a cautious approach to Greater China," said CFO Matthew Friend.
Playtika Stock Surges On Report of Joffre Capital Interest in Online Casino Gaming Group
Axios reported late Monday that tech buyout group Joffre Capital is seeking a majority stake in the online casino video game group.
Walgreens Stock Slides As Group Scraps Plan to Sell UK-based Boots
"As a result of market instability ... no third party has been able to make an offer that adequately reflects the high potential value of Boots," Walgreens said.